
J-113863
CAS No. 353791-85-2
J-113863( —— )
Catalog No. M22691 CAS No. 353791-85-2
J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect. J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8?nM for human and mouse CCR1 receptors, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 71 | In Stock |
![]() ![]() |
5MG | 115 | In Stock |
![]() ![]() |
10MG | 155 | In Stock |
![]() ![]() |
25MG | 287 | In Stock |
![]() ![]() |
50MG | 500 | In Stock |
![]() ![]() |
100MG | 718 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameJ-113863
-
NoteResearch use only, not for human use.
-
Brief DescriptionJ-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect. J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8?nM for human and mouse CCR1 receptors, respectively.
-
DescriptionJ-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect. J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8?nM for human and mouse CCR1 receptors, respectively. The chemotaxis of the following cells were inhibited by J-113863. Modified Vaccinia virus Ankara (MVA) but not MVA and vaccinia virus (VACV) infected MH-S cells increase the expression of the CXCR2 acting chemokine CXCL2. MH-S cells constitutively produce CCL2 and CCR1 acting chemokines CCL3, CCL5 and CCL9. Consequently, supernatants of mock treated and virus infected MH-S cells induce chemotaxis of murine promyelocyte MPRO cells and human monocytic THP-1 cells at the same level. However, supernatants of MVA infected MH-S cells significantly increase chemotaxis of the CCR2 deficient human monocytic cell line U-937. J-113863 treatment improves paw inflammation and joint damage, and dramatically decreases cell infiltration into joints in arthritic mice.
-
In Vitro——
-
In VivoAnimal Model:DBA-1 male mice (10-12 weeks) induced with Collagen Dosage:3 mg/kg, 10 mg/kg Administration:Intraperitoneal injection; once daily; for 11 days Result:Improved paw inflammation and joint damage, and dramatically decreased cell infiltration into joints.
-
Synonyms——
-
PathwayAutophagy
-
TargetCCR
-
RecptorCCR1|CCR3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number353791-85-2
-
Formula Weight655.44
-
Molecular FormulaC30H37Cl2IN2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (76.28 mM)
-
SMILES[I-].CC[N+]1(C\C2=C\CCCCCC2)CCC(CC1)NC(=O)C1c2cc(Cl)ccc2Oc2ccc(Cl)cc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lehmann MH, et al. Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage. Virol J. 2015 Feb 12;12:21.
molnova catalog



related products
-
CCR1 antagonist 6
CCR1 antagonist 6 is a CCR1 antagonist (IC50: 3 nM).
-
Maraviroc
Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM, respectively.
-
Cenicriviroc
Cenicriviroc is an orally active, dual antagonist of CCR2/CCR5. It also inhibits both HIV-1 and HIV-2, and displays potent anti-infective and anti-inflammatory activity.